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NTRODUCTION
Graft-vs.-host-disease (GVHD) and associated infections
remain major determinants of morbidity and mortality follow-
ing allogeneic marrow grafting [1,2]. In a previous contro l l e d
trial we found that the rates of acute GVHD, interstitial pneu-
monia, and infection were reduced in adults who re c e i v e d
intravenous immunoglobulin (IVIg) prophylaxis following
m a rrow transplantation from related marrow donors [3]. In
that study, IVIg initially was given at a weekly dose of
500 mg/kg until day 90, then monthly until day 360 post-
transplant. This 12 g/kg regimen (500 mg/kg for 24 infusions)
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ABSTRACT
Graft-vs.-host disease (GVHD) and infection are major complications of allogeneic bone marrow transplantation.
Intravenous immunoglobulin (IVIg) given at a dose of 500 mg/kg/wk has been shown to decrease the risk of acute
GVHD, interstitial pneumonia, and infection in adults early after allogeneic transplantation. The current study is a
c o n t rolled trial to determine whether a lower total dose of IVIg given with pretransplant loading reduces the inci-
dence of transplant-related complications. In a randomized trial of 241 patients $20 years of age who were given
related donor marrow allografts, 121 individuals receiving Ig prophylaxis (500 mg/kg/d loading from day –6 to –1
and then 100 mg/kg every 3 days from day 3 to 90) were compared with 120 control patients who did not re c e i v e
IVIg. Randomization was stratified by human leucocyte antigen–matching, remission status of malignancy, GVHD
p rophylaxis, and cytomegalovirus (CMV) sero l o g y. The study was powered to detect a reduction in acute GVHD by
18% and a decrease in transplant-related mortality by 17%. Pretransplant IVIg loading and posttransplant mainte-
nance achieved median serum IgG levels .1350 mg/dL, which were approximately twofold greater than the
u n t reated controls (p , 0.01). White blood cell and platelet recoveries were similar for the two groups, although
c o n t rol patients re q u i red fewer units of platelets per day (2.5 vs. 3.3, p 5 0.008). No significant diff e rences in the
incidence of CMV infection, interstitial pneumonia, or bacteremia were observed. The incidence of acute GVHD
did not differ between the two groups; however, acute GVHD was less frequent among IVIg recipients achieving
maximum serum IgG levels .3000 mg/dL (60 vs. 79%). Neither transplant-related mortality nor disease-free sur-
vival was significantly altered by Ig prophylaxis. However, the cumulative incidence of relapse of malignancy was
higher in IVIg recipients than in controls (31 vs. 18%, p 5 0.03). Multivariable re g ression analysis demonstrated a
1.89 increased relative risk of relapse for individuals given IVIg (p 5 0 . 0 2 1 ) . We conclude that pretransplant loadi n g
and a shorter course and lower total dose of IVIg prophylaxis did not appear to decrease the risk of acute GVHD or
m o rtality among adults receiving related donor marrow transplants. Note, IVIg administration may be associated
with an increased risk of re c u rrent malignancy, a finding that warrants further investigation.
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was lower than the 19 g/kg regimen re p o rted by Wi n s t o n
et a l . [4] (1000 mg/kg for 19 infusions), which also showed a
s i g n i ficant reduction in acute GVHD. Recently, in a random-
ized trial comparing doses of 250 and 500 mg/kg of IVIg given
to transplant recipients weekly from day –8 to day 111, Abdel-
Mageed et al. [5] demonstrated that the higher dose was asso-
ciated with less acute GVHD (p 5 0 . 0 3 ) .
Pharmacokinetic studies of IVIg administration in mar-
row graft recipients have shown a shortened serum IgG
half-life relative to nontransplant individuals [6–9], and con-
tinuous infusion of IVIg appears to yield higher IgG levels
than does intermittent dosing [10]. Cottler-Fox et al. [ 1 1 ]
observed that after receiving IVIg at 500 mg/kg/wk, patients
who developed acute GVHD had significantly lower trough
IgG levels (,1200 mg/dL) at and after day 20 posttrans-
plant than did patients without GVHD (trough levels
$1200 mg/dL). Pharmacokinetic modeling by these investi-
gators determined that when analyses were restricted to days
before the diagnosis of GVHD, serum IgG patterns did not
significantly differ between GVHD and non-GVHD groups
[12]. However, once patients developed GVHD, their serum
IgG levels decreased more rapidly than in individuals free of
GVHD. 
If serum levels of IgG were of causal importance in
modifying GVHD, then intensive IVIg loading before
transplantation followed by replacement maintenance dos-
ing might further enhance the beneficial effect. The follow-
ing controlled trial was designed to test whether pre t r a n s-
plant loading of IVIg with a lower and less costly 6 mg/kg
total dose would decrease the incidence of acute GVHD and




The trial was a stratified randomized comparison of
patients who received Ig prophylaxis and control patients
who did not. Study endpoints were acute GVHD and
t r a n s p l a n t - related mort a l i t y. Stratification factors for ran-
domization included type of marrow transplant (human
leukocyte antigen [HLA]-identical or HLA-nonidentical),
remission status of malignancy, cytomegalovirus (CMV)
s e rostatus, and GVHD prophylaxis. Patients were eligible
for study if they were $20 years of age and underg o i n g
related donor marrow transplantation for hematologic
m a l i g n a n c y.
Kinetic values in a one-compartment model with first-
o rder elimination allowed estimation of the IVIg schedule
needed to reach and maintain a desired serum concentra-
tion. Using values re p o rted by Schiff [13] of volume of dis-
tribution 5 0.5 L/kg, half-life 5 25 days, and serum clear-
ance 5 2 mL/kg/d, re s p e c t i v e l y, we derived estimates of
loading and maintenance doses of IVIg re q u i red to main-
tain an average serum concentration. A loading dose of 500
mg/kg/d for 6 days was calculated to produce a serum IgG
concentration of ~4500 mg/dL at the end of the sixth infu-
sion. To achieve a steady-state IgG concentration of 1700
mg/dL through day 75, the estimated maintenance dosing
re q u i red was 100 mg/kg IVIg given e v e ry 3 days after
loading. 
Treatment pr o t o c o l
Consent forms were approved by the institutional re v i e w
b o a rd. To evaluate pharmacokinetic models, nine pilot
patients received 500 mg/kg infusions of IVIg through a Hick-
man catheter from days –6 to –1 pretransplant. These patients
did not receive additional IVIg. Subsequent study patients
w e re randomized to receive IVIg infusions of 500 mg/kg daily
f rom days –6 to –1 pretransplant followed by 100 mg/kg
e v e ry third day posttransplant from day 3 to day 90 (total
6 g/kg). The rate of infusion was 0.01 mL/kg/min for the
initial 15 minutes, followed by 0.02 mL/kg/min for 15 min-
utes, followed by 0.04 mL/kg/min for 30 minutes, and then
0.08 mL/kg/min thereafter.
The IVIg product (Gamimune Ν; Cutter Biological,
Miles, West Haven, CT) was manufactured using the Cohn-
Oncley method of cold ethanol fractionation and purified by
diafiltration with water at pH 4 [3,13].
Transplantation r e g i m e n
The characteristics of the study groups are presented in
Table 1. Pat ients were pre p a red for transplant with
cyclophosphamide (120 mg/kg) and either busulfan or, more
c o m m o n l y, total-body irradiation from opposing cobalt
Table 1. Patient characteristics
Factor IVIg No IVIg 
Number of patients 120 121
Age
20–39 years 64 67
40–60 1 years 56 54
Disease 
Malignancy-Rem or CP 57 54






CY 1 .1200 cGy TBI 50 59
BU/CY 30 24




CSP 1 MTX 79 81
CSP alone 8 10
CSP 1 prednisone 12 8
MTX alone 5 5
Other 13 16
T-cell–depleted 3 1
Growth factors 17 15
Pentoxifylline 38 32
CMV seropositive 65 70
Entered LAF 37 39
Second transplant 8 3
BC, blast crisis; BU, busulfan; CMV, cytomegalovirus; CP, chronic phase;
CSP, cyclosporine; CY, cyclophosphamide; IVIg , intravenous immunoglobulin;
LAF, laminar air flow; MTX, methotrexate; Rel, relapse; Rem, remission;
TBI, total-body irradiation.
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s o u rces in fractionated total doses of 12–15.75 Gy given
over several days at 6–7 cGy per minute. The day of marrow
infusion was designated day 0. Most individuals re c e i v e d
GVHD prophylaxis with methotrexate and cyclosporine
[14]. The assessment and grading of acute and chro n i c
GVHD have been previously described [15,16]. Acute
GVHD of grades II–IV severity was treated with methyl-
p rednisolone (2 mg/kg/d), antithymocyte globulin (15
mg/kg given daily for six doses), cyclosporine (3 mg/kg/d
intravenously or 12.5 mg/kg/d orally), or a combination of
these agents [17]. Chronic GVHD was treated with pre d-
nisone alone (1 mg/kg every other day) or in combination
with cyclosporine (12.0 mg/kg every other day) [18,19].
S u p p o rt i v e care
The following care was routinely given to both Ig
recipients and control patients. To prevent P n e u m o c y s t i s
c a r i n i i infection, administration of trimethoprim/sul-
famethoxazole was initiated in each patient on arrival at the
transplant center and continued until day –2. Upon re t u rn
of neutrophil counts to $5 0 0 / m m3 for 2 days consecutively,
trimethoprim/sulfamethoxazole was resumed twice weekly
until day 180. To prevent exogenous acquisition of primary
CMV infection, all seronegative patients with sero n e g a t i v e
m a rrow donors received red blood cell and platelet transfu-
sions from seronegative blood donors exclusively [20,21].
S e ropositive patients did not receive screened blood pro d-
ucts. To prevent endogenous reactivation of CMV in
s e ropositive patients, ganciclovir was initiated at engraft-
ment (absolute neutrophil count .7 5 0 / m m3 for 2 days
consecutively) and administered at a dose of 5  m g / k g
twice daily for 5 days followed by 5 mg/kg/d 6 days per
week until day 100, or whenever CMV antigenemia devel-
oped [22]. To prevent reactivation of herpes simplex viru s
in seropositive patients, acyclovir 250 mg/m2 twice daily
was started on the day of conditioning and given until day
30, or the day of hospital discharge if it occurred before day
30. Acyclovir was discontinued if ganciclovir was initiated.
Ceftazidime was used prophylactically during neutro p e n i a
to prevent bacterial infection. Fluconazole was given for
fungal prophylaxis from the start of conditioning thro u g h
day 75 posttransplant [23].
Ig could be given off protocol under only three condi-
tions: 1) patients in either group could receive ganciclovir
and Ig for treatment of CMV pneumonia that was confirm e d
by tissue examination [24], 2) patients in the control gro u p
could receive Ig as necessary if hypogammaglobulinemia
(IgG levels ,500 mg/dL) developed, and 3) patients in either
g roup could receive Ig for treatment of idiopathic thro m b o-
cytopenia purpura to control bleeding or to permit surg e ry.
In both study groups, serum IgG levels were tested
b e f o re protocol entry, on days –3 through 7, and on days 30,
60, 90, 120, 150, 180, 270, and 360. Patients entered into the
p h a rmacokinetics study had testing discontinued after day 90.
Definition and evaluation of inf e c t i o n
The following conventions were established before the
study began. Bacteremia was defined as the occurrence of
one or more blood cultures positive for any org a n i s m ,
re g a rdless of associated symptoms. Septicemia was defin e d
as the occurrence of bacteremia in conjunction with
hypotension (systolic blood pre s s u re ,90 mmHg or dias-
tolic blood pressure ,60 mmHg) or disseminated intravas-
cular coagulation (decreased fibrinogen and increased fibrin
degradation products) documented within 24 hours of the
positive blood cultures. Cellulitis was defined as a localized
erythema and swelling associated with either a positive aspi-
rate or biopsy culture for an organism other than coagulase-
negative Staphylococcus or a positive blood culture (or two
positive blood cultures when the organism was coagulase-
negative Staphylococcus) in the absence of a positive local
culture. Pneumonia was defined as a new or progressive pul-
m o n a ry radiographic infiltrate and the identification of an
infectious pathogen by bronchial alveolar lavage, bronchial
washing, or biopsy of lung parenchyma. A Hickman
catheter infection was denoted as either a local erythema at
the exit site with purulent drainage positive for a single or
p redominant organism or inflammation (including re d n e s s
and tenderness) at least 1 cm or more up the line from the
exit site or at any other point along the tract with an associ-
ated positive blood culture in the absence of a positive local
site culture. Urinary tract infection was defined as a urine
culture with $50,000 colonies of a single organism with or
without symptoms. Seronegativity for CMV was indicated
by negative serologic result (titer ,1:8) by both latex agglu-
tination and complement fixation. CMV infection was
demonstrated by isolation of the virus from any site in pre-
viously uninfected patients, whereas CMV disease was indi-
cated by any tissue evidence of virus with associated signs
and symptoms of infection. 
Viral, fungal, and bacterial cultures were ro u t i n e l y
obtained from biopsy and autopsy specimens and during
diagnostic evaluations of fever. Patients were examined for
infection daily in the hospital and at least weekly in the
clinic until discharge from the Seattle center, which
occurred a median of 99 days after transplantation. 
Pa t i e n t s
A total of 260 patients were re g i s t e red and 241 were
evaluable. Those who were nonevaluable received no study
drug. Patients were designated as nonevaluable for the fol-
lowing reasons: randomization to a competing pro t o c o l
(eight patients), refusal to participate after initially enrolling
(six), not having undergone transplantation (two), diagnosis
of multiple myeloma for which IVIg infusions are standard
of care (one), allergy to IVIg (one), and loss of eligibility due
to change in status variables (one). Table 1 shows the char-
acteristics of the study groups.
Statistical anal y s e s
The trial was a two-armed open-label randomized com-
parison of patients who received IVIg and control patients
who did not. The primary endpoints were grades II–IV
acute GVHD and transplant-related mort a l i t y. A sample
size of 240 patients was chosen to allow detection of an
18% decline in the incidence of acute GVHD or a
17% decline in nonrelapse mortality with a statistical power
of $0.80 (a level 5 0.05). 
Descriptive statistics were used to summarize patient
and transplant characteristics within each study gro u p .
Median serum IgG levels were plotted over time for both
the loading period and the maintenance phase. Acute
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GVHD, bacteremia, septicemia, local infections, CMV dis-
ease, interstitial pneumonia, and relapse were summarized
and compared between study arms using cumulative inci-
dence methodology [25]. This approach is necessary because
all endpoints are subject to the competing risk of death as
well as to ord i n a ry censoring. The endpoint of transplant-
related mortality has the competing risk of relapse, and so
was also analyzed using cumulative incidence. Disease-fre e
s u rvival was summarized graphically with Kaplan-Meier
c u rves and compared between study arms by logrank test.
Cox re g ression analysis was used to assess risk factors in
multivariable models.
Figure 1.
Kinetics of pretransplant intravenous immunoglobulin (IVIg) loading in nine pilot study patients. Posttransplant IVIg was not given. Values are means 6 SE.
Cmax, maximum concentration; CLS, serum clearance; and Vd, volume of distribution. 
Figure 2.
Serum IgG levels (mg/dL) among treatment arm patients during the loading period. Posttransplant IVIg was given.
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RESULTS
Antibody titers, side effects, and engraftment
The kinetics of IVIg loading in nine pilot patients are
displayed in Figure 1. Serum IgG levels during IVIg load-
ing in the randomized patients are presented in Figure 2.
As shown in Figure 3, the treatment group achieved higher
IgG levels than did the controls (p , 0.01). Median IgG
values in IVIg recipients exceeded 1350 mg/dL on days
30–90 posttransplant. Some control patients received sup-
plemental IVIg before day 82 for medical indications, and
o b s e rvations collected on these individuals after administra-
tion of the first dose were excluded from calculation of the
c u rves in Figure 3. Only 10 such patients received their fir s t
dose of IVIg before day 80, whereas another 22 re c e i v e d
the initial dose on days 80–100.
Adverse reactions occurred in eight patients during 10
(0.27%) of the 3704 infusions. These included chills (two
infusions), dizziness (one), bradycardia (one), headache
(one), rash (one), and other symptoms (four). There was no
apparent hepatotoxicity. As shown in Table 2, total bilirubin
levels in the Ig recipients were lower than those in controls
(median 0.85 mg/dL vs. 1.1, p 5 0.03).
Recovery of the white cell counts was similar in the two
study groups. Control patients re q u i red fewer units of
platelets per day than those receiving IVIg (median 2.5 units
vs. 3.3, p 5 0.008). The median day to platelet indepen-
dence did not differ significantly between the two groups.
I n f ection and interstitial pneumonia
Table 3 summarizes infection data in the two cohort s .
The rates of bacteremia, septicemia, and local infection did
not differ significantly between the groups. Coagulase-
negative staphylococcus was the most common isolate.
The overall incidence of CMV infection was not altered in
a statistically significant manner by use of IVIg in CMV
s e ronegative patients (p 5 0.085) or seropositive individu-
als (p 5 0.38). The cumulative incidence of first bactere m i a
in CMV seronegative patients (p 5 0.24) and sero p o s i t i v e
patients (p 5 0.79) also did not diff e r. No significant dif-
f e rences in the incidence of first interstitial pneumonia
w e re noted in CMV seropositive (p 5 0.8) or sero n e g a t i v e
(p 5 0.53) individuals.
Acute GVHD
As shown in Figure 4, grades II–IV acute GVHD were
nearly 20% less frequent among IVIg recipients achieving
maximum serum IgG levels $3000 mg/dL (60% vs. 79%).
H o w e v e r, the cumulative incidence of acute GVHD did not
d i ffer significantly between the two treatment groups as a
whole (placebo 73% vs. IVIg 65%, p . 0.20). The inci-
dence of acute GVHD was similar between treatment arm s ,
both among HLA-identical patients (placebo 67% vs. IVIg
61%) and among HLA nonidentical patients (placebo 90%
vs. IVIg 83%). Administration of IVIg also did not influ-
ence the incidence of grades III–IV acute GVHD (placebo
39% vs. IVIg 38%).
Hospital days and costs
The number of hospital days and days from transplant
to return home were similar for the two groups. Mean hos-
pital and outpatient charges, independent of the cost of
IVIg, also did not differ substantially.
S u r vival, r e l ap s e , and mor t a l i t y
As shown in Figure 5, overall survival at 6 years did not
differ between control and treatment groups (placebo 49%
vs. IVIg 38%, p 5 0.11). We noted a trend toward decreased
disease-free survival in IVIg recipients compared with con-
trols (p 5 0.07). The magnitude of the increase in risk was
similar for HLA-identical individuals and HLA-nonidenti-
cal recipients (relative risk 5 1.4 in both subgroups). Trans-
p l a n t - related mortality did not differ between tre a t m e n t
g roups (p 5 0.92). As shown in Figure 5, the cumulative
incidence of overall relapse was greater among patients
Figure 3.
Median serum IgG levels (with 25th and 75th percentiles) of IVIg recipients and controls who did not receive Ig.
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r a ndomized to receive IVIg (31% vs. 18%, p 5 0.03). Cox
regression analysis, adjusting for stage of malignant disease
at transplant and donor type (HLA-identical, HLA-non-
identical, or T-cell–depleted) revealed a 1.89 increased rela-
tive risk of relapse among IVIg patients compared with
c o ntrols (p 5 0.021).
DISCUSSION
The current study found that patients randomized to
receive pretransplant loading and subsequent reduced doses
of IVIg did not have a significant reduction in acute GVHD
c o m p a red with patients who did not receive Ig. However,
among HLA-identical patients .20 years of age tre a t e d
with IVIg in the current study, the 61% cumulative inci-
dence of grades II–IV acute GVHD was substantially higher
than the 28% incidence in adult IVIg recipients in our pre-
vious report [3], despite a similar methotrexate/cyclosporine
regimen for GVHD prophylaxis. Factors influencing the
development of acute GVHD include HLA matching, stage
of malignant disease at transplantation, intensity of the
p reparative regimen, patient age, GVHD prophylaxis, and
d o n o r- recipient gender [26–31]. To better understand the
effect of IVIg on acute GVHD in the prior and the current
randomized trials, data from the previous study were reeval-
uated using only related allogeneic recipients .20 years old.
Of the 264 patients selected, major differences in risk factors
for GVHD between the studies were not noted.
Given that these factors did not differ between the two
trials, the increased incidence of acute GVHD in the cur-
rent study might be attributable to lower serum IgG levels
achieved due to the reduced IVIg dosing. Catabolism of IgG
follows a multicompartmental model of first-order elimina-
tion [13]. Numerous studies in primary immunodefic i e n c y
disease patients indicate a half-life of IgG of 23 days or
g reater [32,33]. However, serum concentrations may not
follow first-order kinetics over a broad range of concentra-
tions and disease states [34]. Pharmacokinetic studies of
IVIg in marrow graft recipients are inconsistent; some
re p o rt findings similar to those expected for healthy sub-
jects, whereas many others suggest a shortened half-life of
~3–10 days [6–9]. Using values re p o rted by Schiff [13] for
volume of distribution, half-life, and clearance of IVIg in
p r i m a ry immunodeficiency patients, a loading dose of
500 mg/kg/d for 6 days was estimated to produce a serum
concentration of about 4500 mg/dL at the end of the sixth
infusion. This was nearly achieved in the pilot study of nine
patients demonstrating a peak serum IgG concentration of
4027 6 165 mg/dL. Because of the decreased half-life and
i n c reased clearance of IgG observed in marrow allografts,
patients were maintained on a dosage of 100 mg/kg IVIg
every 3 days to sustain a target steady-state concentration of
~1700 mg/dL. Failure to achieve these levels of serum IgG
may be explained by the reduced half-life and incre a s e d
clearance of IVIg in transplant recipients compared with
patients with primary immunodeficiency. Unique circ u m-
stances in marrow graft recipients such as pro t e i n - l o s i n g
e n t e ropathies, increased macrophage priming, and acute
GVHD may further explain some of the observed diff e re n c e s
[35–37]. Despite there being no significant diff e rence in
cumulative incidence of grades II–IV acute GVHD between
randomized groups in the current study, the potential impor-
tance of serum IgG levels was demonstrated by the fin d i n g
that acute GVHD was less frequent among patients achiev-
ing maximum serum IgG levels .3000 mg /dL. It is unclear,
however, whether this is a cause or an effect in relation to
the development of GVHD.
Table 3. Posttransplant infections
Factor No IVIg IVIg 
Number of infections per patient 
No infection 31 (26%) 32 (27%)
1 36 (30%) 33 (28%)
2 14 (12%) 21 (18%)
3–4 26 (21%) 17 (14%) 
$5 14 (11%) 17 (14%)
Total 121 (100%) 120 (100%)
Organisms
CN staphylococcus 46 47
Herpes simplex virus 22 26 
Clostridium difficile 16 25
Candida 7 13 
Aspergillus 5 10 
Cytomegalovirus 10 3
Other organisms 136 126 
Total 242 250
Rates/100 days (day 0–100) 
Patient days at risk 10,903 10,419 
Septicemia 0.13 0.07 
Bacteremia 0.77 1.13 
Local infection 1.32 1.20
CN, coagulase negative. 
Table 2. Posttransplant events
Factor No IVIg IVIg
Engraftment (median day)
ANC . 200 17 17
ANC . 500 20 20
ANC . 1000 23 23
Platelet recovery (median)
Days to platelets .50,000 36 33
Days to last platelet transfusion 70 55
Days of platelet transfusions 37 25
Units/d 2.5 ( p 5 0.008) 3.3
Total units 100 115
Median day 90 liver function tests
AST 34 41
Alkaline phosphatase 74 92
Total bilirubin 1.1 ( p 5 0.03) 0.85
Mean days
First hospital stay 30 31
Total hospital stays 40 41
BMT to day home 99 96
ANC, absolute neutrophil count; AST, aspartate aminotransferase; BMT, bone
marrow transplant; IVIg, intravenous immunoglobulin.
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Differences in neither risk factors for acute GVHD nor
serum IgG levels can explain the discrepancy in incidence of
acute GVHD among HLA-identical controls in the current
and previous studies (67% vs. 43%). The increased inci-
dence of acute GVHD for both control patients and those
receiving IVIg may, in part, be related to differences in the
e x p ression or grading of acute GVHD or other curre n t l y
unrecognized factors [38].
As described in a meta-analysis of 12 controlled trials of
IVIg prophylaxis after marrow transplantation, for studies
re p o rting endpoints of acute GVHD in 379 patients, the
pooled odds ratio of developing acute GVHD was 0.68
(95% c o n fidence interval, 0.45–1.02) among IVIg re c i p i e n t s
c o m p a red with controls not given IVIg [39]. Overall mort a l-
ity re p o rted in 809 patients showed an odds ratio of mort a l-
ity of 0.74 (0.55–0.99) (values ,1.0 suggest that IVIg was
e ffective). Meta-analysis of controlled trials of IVIg on symp-
tomatic CMV infection showed a pooled odds ratio of 0.55
for CMV seronegative patients and 1.07 for CMV sero p o s i-
tive patients given IVIg. The pooled odds ratio for the eff e c t
Figure 5.
Kaplan-Meier estimates of overall survival among of IVIg recipients and controls and cumulative incidence of relapse of malignancy.
Figure 4.
Cumulative incidence of grades II–IV acute graft-vs.-host disease (GVHD) among IVIg recipients achieving maximum serum IgG levels .3000 mg/dL and
,3000 mg/dL.
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of IVIg on fatal CMV infection was 0.47. In that analysis, the
authors suggested that a significant decrease in fatal CMV
infection without a significant decrease in all symptomatic
CMV infections (when considering CMV negative and
CMV positive recipients together) was consistent with the
t h e o ry that IVIg reduces microbial disease by facilitating a
regulated inflammatory response to infection rather than
d e c reasing the incidence of infection. If this theory is valid,
the lack of a reduction in infection may be due to a failure to
achieve immunomodulatory levels of serum IgG. In addition,
the hypogammaglobulinemia seen in the untreated contro l
patients in the previous study [3] may have been an impor-
tant cofactor. In contrast, hypogammaglobulinemia was less
common in the current control group, and it was tre a t e d
when it occurred. Failure of the current IVIg regimen to
reduce the incidence of interstitial pneumonia and infection
early after transplant may be related to the lower serum IgG
levels achieved or the lack of effect on GVHD and the subse-
quent risk of infection. The latter hypothesis is supported by
the finding that when IVIg is given on a monthly basis, IgG
levels decreased sharply and IVIg prophylaxis had no appar-
ent effect on chronic GVHD or late infection [40].
In the previous trial, transplant-related mortality was
significantly reduced among IVIg recipients .20 years of
age who received HLA-identical marrow [3]. In these adult
patients, relapse rates were similar for IVIg recipients and
untreated controls. The relapse rate, however, was higher in
patients ,20 years of age who received IVIg prophylaxis [3].
The data from this pediatric group receiving IVIg were con-
founded by a markedly higher number of patients entering
transplantation programs in relapse compared with controls
who were not given IVIg.
In the present study of adults given related-donor trans-
plants, the cumulative incidence of relapse was greater among
individuals randomized to receive IVIg (31% vs. 18%, p 5
0.03). Multivariable re g ression analysis, adjusting for stage of
disease at transplantation and donor type (HLA-identical,
HLA-nonidentical, or T-cell–depleted) failed to alter this
finding. It is important to note that the 5.7-year median dura-
tion of follow-up in the current study is substantially longer
than the 2.0-year median follow-up in the previous re p o rt .
Thus, the power to discriminate between the two study arm s
i n c reased, perhaps allowing a detection of late diff e re n c e s .
The apparent increased incidence of relapse in patients
randomized to Ig prophylaxis may also be due to other
unknown factors. The immunomodulatory effect of IVIg
in the treatment of autoimmune disease has been well
described [41–44]. In addition, the antileukemic effect of
acute and chronic GVHD is well known [45–47]. Intra-
venous Ig may attenuate this graft-vs.-leukemia eff e c t
without an overt reduction in associated clinical GVHD,
suggesting that the two processes may be more mechanisti-
cally distinct than was previously thought. A multicenter
randomized controlled trial comparing IVIg with placebo
in unrelated-donor marrow recipients has recently com-
pleted the accrual of 500 patients. Before entry, patients
w e re stratified according to factors influencing relapse and
GVHD. This placebo-controlled trial of conventional dose
Ig (500 mg/kg/wk to day 90 without pretransplant loading)
will offer an opportunity to further study the effect of IVIg
on posttransplant disease re c u rre n c e .
In conclusion, pretransplant loading with a short e r
course and lower total dose of IVIg prophylaxis did not
d e c rease the risk of acute GVHD, infection, or mort a l i t y
among adults receiving allogeneic marrow from re l a t e d
donors. Serum IgG levels were lower than those observed in
our previous study and may have lessened the benefit. More-
o v e r, with a longer follow-up period, reduced-dose IVIg may
be associated with an increased risk of posttransplant re l a p s e
of malignancy that appears to be independent of GVHD.
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